Lung (Small Cell) Cancer: S1400 (Iowa Cancer Specialists)

S1400 - Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Objective

This study is for patients that have advanced squamous cell lung cancer and has two steps: the initial screening step where we will examine tumor tissue and the sub-study treatment step where patients will be assigned to a treatment sub-study that is chosen based on the screening results.

The purpose of the study screening step is to perform genetic tests on patient tumor samples for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign patients to a treatment sub-study that is chosen based on the results (genes and proteins called “biomarkers”) of this genetic testing on the patient's tumor sample.

The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer.

Click here for more information from the National Cancer Institute.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Lung (Small Cell)
Sponsor(s)
SWOG
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email